Early clinical data indicates that a new drug combination stopped tumor growth in ninety percent of sixty-one participants diagnosed with advanced pancreatic cancer. The study, reported by MyJoyOnline, found that tumors became undetectable on scans in one out of twelve patients who received daraxonrasib alongside chemotherapy. Medical experts are describing this outcome as the most significant advancement in treating this deadly disease in decades. The participants had recently been diagnosed after the cancer had spread to other body parts.

Daraxonrasib operates as a KRAS inhibitor, targeting specific genetic mutations that drive tumor growth in most pancreatic cases. These same mutations appear in lung and ovarian cancers, suggesting the drug could help broader patient groups. The medication already holds approval in the United States. Dr. Wungki Park of Memorial Sloan Kettering Cancer Centre, involved in the trial, stated the findings are extremely encouraging. He noted that the data reveals higher response rates and doubled disease control duration, which may lead to longer survival times.

Cancer Research UK called the results the biggest leap forward for patients in decades. Dr. Sam Godfrey told BBC News that the drug targets previously undruggable mutations and expressed hope for expansion to other cancers. However, physicians caution this is not a cure. The trial monitored patients for an average of eighteen months, with some showing no return of cancer during that window. Longer studies remain necessary to determine if remission can be sustained over time.

Pancreatic cancer carries the lowest survival rate among common malignancies in the UK. Cancer Research UK reports 11,500 diagnoses and 10,200 deaths annually in Britain. Traditional chemotherapy often fails to stop regrowth. Most patients with advanced disease survive months, not years. Prof Elena Garralda, chair of the European cancer conference EORTC, said the combined treatment could significantly improve overall survival and delay tumor regrowth.